GlassScriptPhysician profile
Ghazwan Acash
NPI 1710187331
$2,714.62
in general payments reported to CMS, 2019-2025
17 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $713 · 2021: $44.88 · 2022: $175 · 2023: $560 · 2024: $1,091 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $922 · Consulting Fee: $825 · Education: $34.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $922.04 |
| Consulting Fee | $825.00 |
| Education | $34.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gyrus Acmi, INC. | $825.00 | 2024 | |
| Pulmonx Corporation | $741.82 | 2020-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Astrazeneca Pharmaceuticals LP | $307.75 | 2022-2024 | Airsupra, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $229.53 | 2020-2024 | Nucala, Trelegy Ellipta |
| Inari Medical, INC. | $179.10 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Grifols USA, LLC | $77.07 | 2022-2023 | Prolastin-C Liquid |
| Genzyme Corporation | $74.76 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $61.01 | 2022-2023 | Dupixent |
| Ethicon INC. | $40.42 | 2022 | |
| Insmed, INC. | $29.06 | 2025 | Arikayce |
| United Therapeutics Corporation | $27.79 | 2023 | |
| Inspire Medical Systems, INC. | $26.58 | 2025 | Inspire |
| Mylan Specialty L.P. | $21.67 | 2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $21.49 | 2024 | |
| Novartis Pharmaceuticals Corporation | $20.12 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $16.58 | 2022 | |
| Amgen INC. | $14.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghazwan Acash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.